Impact of Nesiritide on Heart Failure Outcomes
Author Information
Author(s): Carroll Richard J, Mulla Zuber D, Hauck Loran D, Westbrook Audrey
Primary Institution: Adventist Health System
Hypothesis
Does nesiritide treatment affect outcomes in patients hospitalized for acute decompensated heart failure?
Conclusion
Nesiritide therapy was associated with increased length of stay and pharmacy cost, but not hospital mortality.
Supporting Evidence
- Nesiritide was associated with a 59% higher odds of hospital mortality initially.
- After adjustments, the odds ratio for hospital mortality became nonsignificant.
- Nesiritide treatment was linked to a prolonged length of stay and elevated pharmacy costs.
Takeaway
This study looked at patients with heart failure and found that using a drug called nesiritide made them stay in the hospital longer and cost more money, but it didn't seem to help them live longer.
Methodology
Retrospective analysis of CHF patients discharged from a hospital system over three years, comparing outcomes based on nesiritide treatment.
Potential Biases
Sicker patients may have been more likely to receive nesiritide, introducing bias.
Limitations
The study design is observational and cannot account for unmeasured confounding factors.
Participant Demographics
Patients were primarily adults aged 18 and older, with a median age of 74 years for those receiving nesiritide.
Statistical Information
P-Value
0.03
Confidence Interval
95% CI: 1.31–1.93
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website